A risk-benefit assessment should be made in patients withfrequent UTIs or fungal genital infections, indwelling urinary catheters, activefoot infections, or at high risk of volume depletion.41 New data are beingexplored in the use of SGLT2 inhibitors among patients with T2D who haveundergone kidney transplantation. Here, SLC5A2 is linked to type 2 diabetes mellitus.